LINC00592 and cervical cancer: In 2018, Yuan et al. revealed that LINC00592 is aberrantly expressed in cervical cancer, and is highly associated with the expression of ZNF20, ZNF441, ZNF573, and TMF1, suggesting that LINC00592 might activate cancer progression via modulating transcription or structural integrity [10].